What’s powering a $26.28 billion opportunity? The global ophthalmology drugs market, valued at US$18.34 billion in 2024 stood ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Berlin: Bayer has received approval from the European Commission (EC) for a label extension in the European Union (EU) for ...

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME: Berlin Saturday, June 28, 2025, 09:00 Hrs [IST] The Eur ...

The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025 and is projected ...

The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME.

Alvotech is also developing AVT29, a proposed biosimilar to Eylea® HD, a higher dose (aflibercept 8 mg) aflibercept. Advanz has licensed the distribution rights from Alvotech for both biosimilar ...

This version of Eylea should continue to steal some patients away from the old formulation due to the former's better dosing schedule. Furthermore, Eylea HD could potentially earn label expansions ...

Bayer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a label extension for Eylea 8 mg ...